Evidence map›Paper›PMID 29922934›Full record

ArticleEuropean radiology2019

Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases.

John M Creasy, Abhishek Midya, Jayasree Chakraborty, Lauryn B Adams, Camilla Gomes, Mithat Gonen, Kenneth P Seastedt, Elizabeth J Sutton, Andrea Cercek, Nancy E Kemeny and 9 more

Abstract read
In one paragraph

Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

John M CreasyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Abhishek MidyaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Jayasree ChakrabortyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Lauryn B AdamsDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Camilla GomesDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Mithat GonenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth P SeastedtDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Elizabeth J SuttonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea CercekDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nancy E KemenyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vinod P BalachandranDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Peter J AllenDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Ronald P DeMatteoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Michael I D'AngelicaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA.
Richard K G DoDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Amber L SimpsonDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-891, New York, NY, 10065, USA. simpsonl@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
National Cancer Institute P30 CA008748 Cancer Center Support GrantNCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectivesThis study investigates whether quantitative image analysis of pretreatment CT scans can predict volumetric response to chemotherapy for patients with colorectal liver metastases (CRLM).

methodsPatients treated with chemotherapy for CRLM (hepatic artery infusion (HAI) combined with systemic or systemic alone) were included in the study. Patients were imaged at baseline and approximately 8 weeks after treatment. Response was measured as the percentage change in tumour volume from baseline. Quantitative imaging features were derived from the index hepatic tumour on pretreatment CT, and features statistically significant on univariate analysis were included in a linear regression model to predict volumetric response. The regression model was constructed from 70% of data, while 30% were reserved for testing. Test data were input into the trained model. Model performance was evaluated with mean absolute prediction error (MAPE) and R

results157 patients were included, split into training (n = 110) and validation (n = 47) sets. MAPE from the multivariate linear regression model was 16.5% (R

conclusionQuantitative imaging features extracted from pretreatment CT are promising predictors of volumetric response to chemotherapy in patients with CRLM. Pretreatment predictors of response have the potential to better select patients for specific therapies. KEY POINTS: • Colorectal liver metastases (CRLM) are downsized with chemotherapy but predicting the patients that will respond to chemotherapy is currently not possible. • Heterogeneity and enhancement patterns of CRLM can be measured with quantitative imaging. • Prediction model constructed that predicts volumetric response with 20% error suggesting that quantitative imaging holds promise to better select patients for specific treatments.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsFemaleHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMiddle AgedMultidetector Computed TomographyNeoplasm StagingReproducibility of ResultsAntineoplastic AgentsColorectal neoplasmsLiverModels, statisticalMultidetector computed tomographyPrognosis

Identifiers

PMID29922934
PMCPMC6301122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.